0001708138-20-000034.txt : 20200415
0001708138-20-000034.hdr.sgml : 20200415
20200415161700
ACCESSION NUMBER: 0001708138-20-000034
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200413
FILED AS OF DATE: 20200415
DATE AS OF CHANGE: 20200415
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STAHL NEIL
CENTRAL INDEX KEY: 0001226689
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20793886
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-04-13
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001226689
STAHL NEIL
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
0
1
0
0
EVP Research and Development
Common Stock
2020-04-13
4
M
0
13079
52.03
A
24459
D
Common Stock
2020-04-13
4
F
0
7582
511.56
D
16877
D
Common Stock
2020-04-14
4
S
0
2
517.99
D
16875
D
Common Stock
2020-04-14
4
S
0
267
518.54
D
16608
D
Common Stock
2020-04-14
4
S
0
422
519.85
D
16186
D
Common Stock
2020-04-14
4
S
0
2096
520.43
D
14090
D
Common Stock
2020-04-14
4
S
0
1595
521.32
D
12495
D
Common Stock
2020-04-14
4
S
0
758
522.37
D
11737
D
Common Stock
2020-04-14
4
S
0
357
524.26
D
11380
D
Common Stock
5736
I
By 401(k) Plan
Common Stock
7831
I
by 2018 GRAT
Common Stock
13700
I
by 2019 GRAT
Non-Qualified Stock Option (right to buy)
52.03
2020-04-13
4
M
0
13079
0.0
D
2021-12-16
Common Stock
13079
25000
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 267 shares of Company stock on April 14, 2020 at prices ranging from $518.14 to $518.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price.
Represents volume-weighted average price of sales of 422 shares of Company stock on April 14, 2020 at prices ranging from $519.27 to $519.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price.
Represents volume-weighted average price of sales of 2,096 shares of Company stock on April 14, 2020 at prices ranging from $520.01 to $520.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price.
Represents volume-weighted average price of sales of 1,595 shares of Company stock on April 14, 2020 at prices ranging from $521.01 to $521.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price.
Represents volume-weighted average price of sales of 758 shares of Company stock on April 14, 2020 at prices ranging from $522.00 to $522.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price.
Represents volume-weighted average price of sales of 357 shares of Company stock on April 14, 2020 at prices ranging from $524.00 to $524.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 14, 2020 at each separate price.
With respect to 75,000 underlying shares (of which 25,000 remain outstanding) the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.
/s/**Neil Stahl
2020-04-14